Cited by 63Venous Thromboembolism Diagnosis and ManagementMenopause: Health Impacts and TreatmentsLGBTQ Health, Identity, and Policy

Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy

Open access
Goldstein, Zil, Khan, Musaub, Reisman, Tamar, Safer, Joshua D·2019·Journal of Blood Medicine

Abstract

Introduction: Venous thromboembolism (VTE) is a potential risk of estrogen therapy. However, data show an improvement in the quality of life for transgender people who use feminizing hormone therapy. With few transgender-specific data, guidance may be drawn from cisgender (nontransgender) data, with a focus on hormonal birth control and postmenopausal hormone replacement therapy (HRT). The aim of this review is to examine the degree to which routes of administration, patient comorbidities, and type of hormone utilized affect the safety of estrogen therapy. Methods: We identified 6,349 studies by searching PubMed with the terms “transgender”, “estrogen”, “VTE”, and “HRT”. Of these, there were only 13 studies between 1989 and 2018 that investigated the effects of hormone therapy, including types of estrogens used, in transgender women and men. Results: The data suggest that the route of hormone administration, patient demographics, and patient comorbidities all affect estrogen’s link with VTE. For example, avoiding ethinyl estradiol might make the use of hormone therapy in trans feminine individuals safer than oral birth control. Data from both cis and trans groups suggest additional VTE risk associated with the use of progestins. While transdermal estrogens dosed up to 0.1 mg/day or below appear lower risk for VTE than other forms of estrogen, it is unclear whether this is related to the delivery method or a dose effect. Finally, even if the risk from exogenous estrogen use remains significant statistically, the absolute clinical risk remains low. Conclusion: Clinicians should avoid the use of ethinyl estradiol. Additionally, data suggest that progestins should be avoided for transgender individuals. Further study of the relationship between estrogen use and the risk of VTE will serve to inform the safest care strategies for transgender individuals. Keywords: transgender, estrogen therapy, venous thromboembolism

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/jbm.s166780

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oral estrogens have similar effects on surrogate inflammatory endpoints in transgender women as in cisgender women, including elevation in proinflammatory cytokines IL-1, IL-6, IL-8, and TNF-α.

    “Oral estrogens seem to have similar effects on surrogate inflammatory endpoints in transgender women as they do in cisgender women [117], such as elevation in proinflammatory cytokines IL-1, IL-6, IL-8, and tumor necrosis factor-α [118].”

    From Estrogen and thrombosis: a bench to bedside review (2020) · cites this paper as [117]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [9]Asscheman, Asscheman H, Giltay EJ, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011; 164: 635– 642. doi: 10.1530/EJE-10-1038 21266549 · DOI
  2. [17]Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344(8935):1453–1457 7968118
  3. [33]Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med. 2018; 169: 205– 213. doi: 10.7326/M17-2785 29987313 PMC6636681 · DOI · Paper page

Cited by

Sorted by citations

Authors
Goldstein, Z., Khan, M., Reisman, T., & Safer, J. D.
Affiliations
  • Mount Sinai Health System (US)
  • New York Medical College (US)
Corresponding author
Safer, Joshua D
Venue
Journal of Blood Medicine
Published
2019-07
Volume
Volume 10
Pages
209-216
ISSN
1179-2736 (ISSN-L)
OpenAlex
W2957469563
Cited by
63
References
38
Citations by year
2026: 5 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 8
FWCI
6.13
Type
journal article
Language
en
Open access
Locations
  • Journal of Blood Medicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Social Sciences › Psychology › Social Psychology › LGBTQ Health, Identity, and Policy
Keywords
venous thromboembolism, transgender adults, feminizing hormone therapy, estrogen therapy, ethinyl estradiol, progestins, transdermal estrogen, hormone replacement therapy, hormonal contraception, thrombosis risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review